A Strong Crenessity Launch And Muscarinic Pipeline Can Propel Neurocrine Biosciences Further

Core Insights - Neurocrine Biosciences (NBIX) has experienced a mixed performance, with shares increasing approximately 12% [1] Company Performance - The stock performance of Neurocrine has slightly outperformed expectations compared to analysts' predictions [1]